Trials / Completed
CompletedNCT00957996
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
A Phase 3, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Infection
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 234 (actual)
- Sponsor
- BioCryst Pharmaceuticals · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peramivir | 300 mg twice daily |
| DRUG | Peramivir | 600 mg once daily |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-10-01
- Completion
- 2011-08-01
- First posted
- 2009-08-13
- Last updated
- 2015-02-12
- Results posted
- 2015-02-12
Locations
110 sites across 6 countries: United States, Australia, Canada, Mexico, New Zealand, Puerto Rico
Source: ClinicalTrials.gov record NCT00957996. Inclusion in this directory is not an endorsement.